Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1417-1422

  Solomon, Benjamin ^a   Binns, David ^a   Roselt, Peter ^a   Weibe, Leonard I ^b   McArthur, Grant A ^a   Cullinane, Carleen ^a   Hicks, Rodney J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROAZOMYCIN ARABINOSIDE F 18; GEFITINIB; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; QUINAZOLINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; EX VIVO STUDY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MOUSE STRAIN; NON INVASIVE MEASUREMENT; NONHUMAN; NUDE MOUSE; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; XENOGRAFT; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; DRUG ANTAGONISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FLUORINE RADIOISOTOPES; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NITROIMIDAZOLES; OXIDATION-REDUCTION; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 33644688465     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0066     Document Type: Article

References (22)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
2. Brown JM. The hypoxic cell: a target for selective cancer therapy - 18th Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863-70.
3. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
4. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
5. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004;90:566-72.
6. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3250-8.
7. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-6.
8. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 55:713-23.
9. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-61.
10. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
11. Reischl G, Ehrlichmann W, Bieg C, et al. Preparation of the hypoxia imaging PET tracer [(18)F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005;62:897-901.
12. Surti S, Karp JS. Design evaluation of A-PET: a high sensitivity animal PET camera. Trans Nucl Sci 2003;50:1357-63.
13. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995;72:889-95.
14. Raleigh J, Calkins-Adams D, Rinker L, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58: 3765-8.
15. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res 2000;6:855-62.
16. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998;71:270-7.
17. Sorger D, Patt M, Kumar P, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-26.
18. Khalil AA, Horsman MR, Overgaard J. The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. Acta Oncol 1995;34:297-300.
19. Jenkins WT, Evans SM, Koch CJ. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys 2000;46:1005-17.
20. Warburton C, Dragowska WH, Gelmon K, et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004;10:2512-24.
21. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
22. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.